Prime Medicine to Present at 41st Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Prime Medicine, Inc. (Nasdaq: PRME) announced that CEO Keith Gottesdiener will present a corporate overview at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023, at 8:15 a.m. PT in San Francisco, CA. The event will be available via live audio webcast on the company's website, with a replay accessible for 30 days post-presentation. Prime Medicine focuses on innovative genetic therapies using Prime Editing technology, which aims to address a wide range of diseases by potentially repairing 90% of known genetic mutations.

CAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Keith Gottesdiener, M.D., President and Chief Executive Officer of Prime Medicine, will present a corporate overview at the 41^st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 8:15 a.m. PT (11:15 a.m. ET) in San Francisco, CA.

A live audio webcast of the presentation will be available under “Events & Presentations” in the News & Events section of the Company’s website at www.primemedicine.com. A replay of the webcast will be available on the Prime Medicine website for 30 days following the presentation.

About Prime Medicine
Prime Medicine is a biotechnology company committed to delivering a new class of differentiated, one-time, curative genetic therapies to address the widest spectrum of diseases. The company is deploying Prime Editing technology, a versatile, precise, efficient and broad gene editing technology, which is designed to make only the right edit at the right position within a gene. With the theoretical potential to repair approximately 90 percent of known disease-causing genetic mutations across many organs and cell types, medicines based on Prime Editing, if approved, could offer a one-time curative genetic therapeutic option to a broad set of patients.

Investor Contact
Hannah Deresiewicz
Stern Investor Relations, Inc.
212-362-1200
hannah.deresiewicz@sternir.com

Media Contact
Dan Budwick, 1AB
dan@1ABmedia.com

FAQ

When is Prime Medicine presenting at the J.P. Morgan Healthcare Conference?

Prime Medicine will present on January 9, 2023, at 8:15 a.m. PT.

Where can I watch the Prime Medicine presentation live?

The presentation can be viewed live on Prime Medicine's website under the 'Events & Presentations' section.

What technology does Prime Medicine use for genetic therapies?

Prime Medicine uses Prime Editing technology, designed to make accurate edits to genes.

How many genetic mutations can Prime Editing potentially repair?

Prime Editing has the theoretical potential to repair approximately 90% of known disease-causing genetic mutations.

What type of company is Prime Medicine?

Prime Medicine is a biotechnology company focused on developing one-time curative genetic therapies.